Preprint
Article

This version is not peer-reviewed.

Prognostic Factors in Real World Patients Receiving Durvalumab After Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC) – The Experience of Oncology Institute “Prof. Dr. Ion Chiricuta”

Submitted:

17 November 2026

Posted:

18 November 2026

You are already at the latest version

Abstract
Purpose and methods: We aimed to evaluate in rw pts, the safety profile, effectiveness and prog-nostic factors associated with the RR, PFS, and secondarily, OS of durvalumab, after c/sCRT, without progression, in LA NSCLC, PD-L1 ≥ 1%. Durvalumab was administered 10 mg/kg at 2 weeks or monthly 1500 mg iv, until disease progression or unacceptable toxicity, no more than a year. Results: Eligible were 75 pts with LA NSCLC, PD-L1 ≥ 1%, but 10 (13.3%) progressed after CRT, thus evaluated were 65 pts. Discontinuation of durvalumab occurred in 23% due to grade ≥ 3 adverse events and in 23% for disease progression. DC in 60% was associated significantly by PS, NC, NLR and AS only approached the significance level. PFS of 30% at 2 years, with a median value of 18 months, was significantly associated with age, PS, NC, NLR, AS. In the multivariable analysis significant prognostic factor remained PS and AS approached significance level. OS of 55% at 2 years and mOS was 26.1 months. Conclusions: Durvalumab after CRT in rw pts with LA NSCLC demonstrate a good safety profile, promising RR, PFS and OS, consistent with other rw analyses. Age, PS, AS, NC, NLR, were associated significantly with PFS. PS remained significant prognostic factors, in the multivariable analysis. AS only approached the significance level war-ranting further investigations concerning the role of psychological profile and support in LA NSCLC.
Keywords: 
;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.